ONCOTELIC PROVIDES YE 2022 FINANCIAL RESULTS COMPARED TO YE 2021 PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
April 17, 2023 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) is providing a summary of its financial results for the year...
ReAlta Life Sciences, Inc. Partners With Hope for HIE to Improve Neonatal Brain Injury Outcomes and Quality of Life
April 27, 2022 09:30 ET
|
Hope for HIE
WEST BLOOMFIELD TOWNSHIP, Mich., April 27, 2022 (GLOBE NEWSWIRE) -- ReAlta Life Sciences, Inc. ("ReAlta") a clinical stage, rare disease company addressing life-threatening diseases through...
Neuronascent Announces Third US Patent Issued Covering Therapeutics for Neurodegenerative and Neuropsychiatric Disorders
January 24, 2017 06:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - January 24, 2017) - Neuronascent's U.S. Patent No. 9,539,261, which issued on January 10, 2017, claims methods of stimulating neurogenesis and/or inhibiting neuronal...